

#### Stock Data

Placing Price: 20p  
Gross Proceeds of Placing: £7.85m  
Shares in issue on Admission: 40.4m

#### Company Profile

Sector: Financial Services  
Ticker: IIG  
Exchange: AIM

#### Activities

Intuitive Investments Group plc ('Intuitive', 'IIG', 'the Group') is a newly established investing company incorporated on 11 June 2020 in England & Wales. An investment in the Company will seek to provide investors with exposure to a focused portfolio of fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, wider Europe and the US.

Company website: <https://www.iigplc.com>

#### IIG Board of Directors

- David Evans, Executive Chairman
- Robert Naylor, CEO Designate (Feb 2021)
- Malcolm Gillies, Ind Non-Executive Director
- Cormac Kilty, Ind. Non-Executive Director
- Colin Willis, Ind. Non-Executive Director

#### Turner Pope contact details

Turner Pope Investments (TPI) Ltd  
8 Fredericks's Place  
London  
EC2R 8AB

Tel: 0203 657 0050  
Email: [info@turnerpope.com](mailto:info@turnerpope.com)  
Web: [www.turnerpope.com](http://www.turnerpope.com)

#### Disclaimer

**Attention is drawn to the disclaimers and risk warnings at the end of this document.**

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

**TPI is acting as broker and sole bookrunner to the Intuitive Investments Group IPO.**

**Retail clients (as defined by the rules of the FCA) must not rely on this document.**

Barry Gibb

Research Analyst

Tel: 0203 657 0050  
[barry.gibb@turnerpope.com](mailto:barry.gibb@turnerpope.com)

Andrew Thacker

Corporate Broking & Sales

Tel: 0203 657 0050  
[andy.thacker@turnerpope.com](mailto:andy.thacker@turnerpope.com)

Zoe Alexander

Corporate Broking & Sales

Tel: 0203 657 0050  
[zoe.alexander@turnerpope.com](mailto:zoe.alexander@turnerpope.com)

# Intuitive Investments Group

## AIM IPO - Life Sciences Focused Investing Company

IIG has today been Admitted onto London's AIM. IIG is an investment group that seeks to leverage the expertise and extensive networks of its Board and Advisory Panel in the multi-billion-dollar Life Sciences sector to drive value creation in its Investee Companies. Bringing proven capability in transaction origination and strategic business plan execution, while recognising opportunity and positioning to drive significant growth, the team has come together to create and direct this internally managed alternative investment fund ('AIF'), which has been granted registration by the FCA as a [small registered UK AIFM pursuant to regulation 10\(2\)](#). Ensuring the Board and Advisory Panel objectives are fully aligned with those of IIG shareholders, together they contributed c.£1.3 million of the Group's £7.85m IPO fundraise. Turner Pope acted as Broker and Sole Bookrunner to this IPO.

### Investment Objective

IIG is the brainchild of Group Chairman, David Evans, who brings 27 years of experience working in diagnostics and life sciences, both privately and as a senior director of a number of listed companies. Having surrounded himself with a team that boasts over 200 years' experience as entrepreneurs and investors, IIG's investment objective is to generate capital growth over the long-term through investment in a focused portfolio of fast growing and high potential Life Sciences businesses operating predominantly in the UK, wider Europe and the US. The Board does not currently intend to utilise debt gearing to enhance shareholder returns, having created a low-cost operating model for the quoted vehicle with annual running cost expected to be less than £420,000.

### Investment Policy

In order to achieve its investment objective, the Group will invest in early and later-stage Life Sciences businesses, stretching across Bio-therapeutics, Pharmaceuticals, Diagnostics & Healthcare, Medical Devices along with related Tools & Technologies. The majority of these will be in unquoted companies, mainly in the form of equity/equity-related instruments (although investments may be made by way of convertible debt instruments in certain circumstances). It may also invest in publicly traded companies and special situations (such as corporate restructuring, etc.) and offer its Ordinary Shares in exchange for those in investee businesses in addition to direct cash investment. Once fully invested, the Group's portfolio is expected to spread risk across approximately 10 to 12 holdings from which it intends to realise value with no fixed investment period. At any time, a least 50% of Group investments must be in unquoted businesses, with no single vehicle representing more than 15% of total investment that is limited to a maximum of 30% seed capital. No material change will be made to the investment policy without prior approval.

### Target Returns

IIG targets a return to shareholders of 20% per annum\*. The Board considers it presently has access to a strong pipeline of opportunities capable of meeting this goal. Capital from subsequent investment realisations may be reinvested, used for working capital purposes or may, at the discretion of the Board, be returned to shareholders by tender offer, share buyback or special dividends although its stated policy is to seek capital growth rather than seek to generate income.

**\*The target return to shareholders is a target only and is not profit or other forecast. There can be no guarantee that this target will be met, and it should not be taken as an indication of expected or actual performance or results.**

## The Intuitive Team – Executive Profile

David Evans - Chairman	Malcolm Gillies	Cormac Kilty	Colin Willis
<ul style="list-style-type: none"> <li>Serial entrepreneur</li> <li>Enabled 12 companies to go public (directly and indirectly) and has overseen four successful exits</li> <li>Extensive experience as chairman of a number of listed life sciences companies, including Omega Diagnostics Group, Immunodiagnostic Systems, BBI Holdings plc, EKF Diagnostics, OptiBiotix Health and Genedrive</li> <li>Chartered Accountant, BCom and MBA</li> </ul>	<ul style="list-style-type: none"> <li>Director of Collagen Solutions, Antoxis, Plasmox, Recircle and Ohmedics</li> <li>Director of Aircraft Medical, sold to Medtronic for \$110 million</li> <li>Company secretary at Axis-Shield</li> <li>Senior corporate partner for over 10 years with Shepherd and Wedderburn</li> </ul>	<ul style="list-style-type: none"> <li>Founder of Biotrin International, Opsona Therapeutics and Argutus Medical</li> <li>Sold Biotrin to Diasorin for €25 million</li> <li>Previously a director of NovaUCD, Nexvet Bioparma</li> <li>Chair of the Irish BioIndustry Association, Awarded Biolink, Life Science Achievement Award</li> <li>PhD in Zoology and Biochemistry</li> </ul>	<ul style="list-style-type: none"> <li>Founding and Managing Director of Hotspur Development Capital</li> <li>Founding Partner at Ignite</li> <li>Director Angel Co-Investment Fund</li> <li>Previously with 3i and Enterprise Ventures</li> </ul>


Source: Investor Presentation October 2020

## The Intuitive Team - Advisory Panel

Dr Stewart White, Chair	Julian Baines MBE	Ron Long	Per Matsson	Alistair Smith
<ul style="list-style-type: none"> <li>Chairman; Novel Technologies Holdings, The Electrospinning Company, Director of CuanTec</li> <li>Previously CEO of Collagen Solutions</li> <li>Visiting Professor University of Glasgow</li> <li>PhD in Bioprocessing, MBA</li> </ul>	<ul style="list-style-type: none"> <li>CEO of EKF Diagnostics</li> <li>Previously Chairman of Renalytix AI</li> <li>Group CEO of BBI sold to Alere Inc in 2008 for circa £85 million</li> <li>MBE for services to the life sciences industry</li> </ul>	<ul style="list-style-type: none"> <li>Previously MD, The Wellcome Foundation</li> <li>Previously CEO of Amersham Pharmacia Life Sciences and Executive Vice Chairman of Amersham</li> <li>CEO or Chairman of several start up business</li> <li>Chairman of Sky Medical Technologies, SVAR Life Sciences AB, Carus and BAR</li> </ul>	<ul style="list-style-type: none"> <li>Previously CTO at Thermo Fisher Scientific</li> <li>ImmunoDiagnostic Division, Head R&amp;D at Sanofi</li> <li>Diagnosics Pasteur, VP R&amp;D Pharmacia Diagnostics</li> <li>Professor at Uppsala University and as Swedish Agricultural University, Faculty of Veterinary Medicine</li> <li>PhD in cell biology</li> </ul>	<ul style="list-style-type: none"> <li>CEO of Avacta since launch</li> <li>Previously Leeds University Chair of Molecular Biophysics</li> <li>PhD in Physics</li> </ul>

Source: Investor Presentation October 2020

## COVID-19 has brought life sciences into sharp focus



Source: Investor Presentation October 2020

**THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.**

### **Conflicts**

This is a non-independent marketing communication under the rules of the Financial Conduct Authority (“FCA”). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited (“TPI”) has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

### **Risk Warnings**

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI’s research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

### **Specific disclaimers**

TPI has been appointed to act as broker to the Intuitive Investment Group plc (‘Intuitive’) in connection with the potential listing of Intuitive securities on the AIM Market of the London Stock Exchange (‘AIM’). TPI’s private and institutional clients may hold, subscribe for or buy or sell Intuitive’s securities.

This document has been produced by TPI independently of Intuitive. Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. Where information utilised in this document has been provided to TPI by Intuitive and/or is attributed to Intuitive or a third-party source, that information has not been subject to any independent verification or evaluation by TPI or any other party. TPI has no authority whatsoever to make any representation or warranty on behalf of Intuitive.

**General disclaimers**

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.